arrow
A

Amir I. Tukhvatulin

ministry of health of the russian federation
H指数:20
被引数:4,280

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structural Design of T-Cell Epitope-Based mRNA Vaccine Constructs Determines the Quality of T-Cell Immunity and Protective Efficacy Against SARS-CoV-2 in Mice

基于T细胞表位的mRNA疫苗构建体的结构设计决定了T细胞免疫的质量以及小鼠中对抗SARS-CoV-2的保护效力

2026-04-040
OAAI
Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents

卫星V疫苗更新:健康成人和青少年中的安全性与中和抗体

2026-03-270
OA
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants

靶向spike NTD的广泛中和单域抗体显示对多种SARS-CoV-2变体的治疗效果

2026-03-270
OAAI
Novel Multistage Subunit Mycobacterium tuberculosis Nanoparticle Vaccine Confers Protection Against Experimental Infection in Prophylactic and Therapeutic Regimens

新型多阶段亚单位结核分枝杆菌纳米粒疫苗在预防和治疗方案中均能提供实验性感染保护

2025-12-191
OA
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge

表达优化后WNV preM/E基因的腺病毒载体可提供对致死性西尼罗病毒攻击的长期保护

2025-11-210
OAAI
Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates

腺病毒载体COVID-19疫苗Sputnik V在非人灵长类动物中诱导的体液免疫反应长期成熟过程中,免疫途径介导的差异

2025-09-190
OAAI
Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia

GamEvac-Combi,一种异源rVSV-和rAd5载体埃博拉疫苗的安全性与免疫原性:一项在几内亚共和国和俄罗斯进行的随机对照多中心临床试验

2025-03-200
OA
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain
2024-12-010
PRE
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

Sputnik V疫苗在hACE2-Transgenic小鼠中针对同源和异源SARS-CoV-2谱系 (包括远距离Omicron BA.5) 的免疫原性和保护性

2024-10-080
OAAI
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
2023-10-201
OAAI
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

基于rAd26和rAd5载体的异源初免-加强新型冠状病毒肺炎疫苗对健康青少年SARS-CoV-2的安全性和免疫原性: 一项开放标签、非随机、多中心、1/2期、剂量递增研究

2023-08-014
OAAI
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection

针对血凝素茎区的交叉反应性Fc融合单域抗体可保护小鼠免受1组甲型流感病毒感染

2022-11-108
OAAI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

鼻内递送的基于载体的异源启动-加强新型冠状病毒肺炎疫苗Sputnik V在小鼠和非人灵长类动物中的免疫原性和保护性

2022-09-2610
OAAI
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

在Sputnik V疫苗接种的个体中保留针对SARS-CoV-2 Omicron变体的中和反应

2022-05-2120
OAAI
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
2021-12-0142
OAAI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Sputnik V疫苗接种人群的血清对关注变体 (VOC: B.1.1.7,B.1.351,P.1,B.1.617.2,B.1.617.3) 和莫斯科地方性SARS-CoV-2变体的中和活性

2021-07-1288
OAAI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和有效性: 俄罗斯一项随机对照3期试验的中期分析

LANCET
IF88.5
2021-02-011.2K
OAAI
Adjuvantation of an Influenza Hemagglutinin Antigen with TLR4 and NOD2 Agonists Encapsulated in Poly(D,L-Lactide-Co-Glycolide) Nanoparticles Enhances Immunogenicity and Protection against Lethal Influenza Virus Infection in Mice
2020-09-1013
OAAI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

两种制剂中基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和免疫原性: 来自俄罗斯的两项开放,非随机1/2期研究

LANCET
IF88.5
2020-09-01732
OAAI